**2026 eCQM Flow**
eCQM Identifier: CMS646v6

NOTE: This flow diagram represents an overview of population criteria requirements. **Refer to the eCQM specification for a complete list of data elements included in this measure and required for submission.**

Intravesical Bacillus-Calmette-Guerin for Non-Muscle Invasive Bladder Cancer

Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging

This eCQM is a patient-based measure

Initial Population

Eligible encounter during the measurement period — No → Do not include in Initial Population

Yes ↓

Diagnosis of bladder cancer — No → Do not include in Initial Population

Yes ↓

Bladder cancer staging within 6 months before to 6 months after the start of the measurement period — No → Do not include in Initial Population

Yes ↓

Diagnosis of T1, Tis, or high grade Ta non-muscle invasive bladder cancer — No → Do not include in Initial Population

Yes ↓

Equals Initial Population (100 patients) [b]

Denominator Exclusions

Evidence of immunosuppression (including HIV and immunocompromised state), with a diagnosis prior to bladder cancer staging — Yes → Denominator Exclusions (20 patients) [x]

No ↓

Presence of immunosuppressive drug therapy starting on or before bladder cancer staging — Yes → Denominator Exclusions (20 patients)

No ↓

Diagnosis of active tuberculosis during the bladder cancer staging — Yes → Denominator Exclusions (20 patients)

No ↓

Presence of mixed histology urothelial cell carcinoma including micropapillary, plasmacytoid, sarcomatoid, adenocarcinoma, and squamous disease prior to bladder cancer staging — Yes → Denominator Exclusions (20 patients)

No ↓

Presence of cystectomy, chemotherapy, or radiation within 6 months prior to bladder cancer staging — Yes → Denominator Exclusions (20 patients)

No ↓

Go to Page 2

Intravesical Bacillus-Calmette-Guerin for Non-Muscle Invasive Bladder Cancer

From Page 1

Numerator

Intravesical Bacillus-Calmette-Guerin (BCG) instillation for initial dose or series: BCG is initiated within 6 months of the bladder cancer staging

Yes → Numerator (40 patients) [a]

No

Denominator Exceptions

Unavailability of BCG within 6 months after bladder cancer staging

Yes → Denominator Exceptions (10 patients) [c]

No

Numerator / Denominator Exceptions not met

Sample Calculation

Performance Rate =

$$\frac{\text{Numerator (a = 40 patients)}}{\text{Denominator (b = 100 patients) - Denominator Exclusions (x = 20 patients) - Denominator Exceptions (c = 10 patients)}} = \frac{40}{70} = 57\%$$

eCQM Identifier: CMS646v6
eCQM Title: Intravesical Bacillus-Calmette-Guerin for Non-Muscle Invasive Bladder Cancer

NOTE: This flow diagram represents an overview of population criteria requirements. Refer to the eCQM specification for a complete list of data elements included in this measure and required for submission

Description: Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging.

This eCQM is a patient-based measure.

eCQM Flow Narrative

Initial Population
Start by identifying the Initial Population, which includes all patients initially diagnosed with T1, Tis or high grade Ta non-muscle invasive bladder cancer with bladder cancer staging within 6 months before to 6 months after the start of the measurement period and a qualified encounter in the measurement period.

Denominator
The Denominator equals the Initial Population. In the sample calculation provided at the end of the eCQM flow, the Denominator is equal to 100 patients.

Denominator Exclusions
The Denominator Exclusions criteria identify a subset of the Denominator population by excluding patients that are immunosuppressed (e.g., HIV and immunocompromised) with a diagnosis prior to bladder cancer staging or are on immunosuppressive drug therapy starting on or before bladder cancer staging. The Denominator Exclusions criteria also excludes patients with an active diagnosis of tuberculosis during the bladder cancer staging; a mixed histology urothelial cell carcinoma including micropapillary, plasmacytoid, sarcomatoid, adenocarcinoma and squamous disease prior to bladder cancer staging; or have undergone cystectomy, chemotherapy or radiation within 6 months prior to bladder cancer staging. In the sample calculation provided at the end of the eCQM flow, the Denominator Exclusions are equal to 20 patients.

Numerator
The Numerator criteria identify a subset of the Denominator population (that did not meet the Denominator Exclusions criteria) by including patients with an intravesical Bacillus-Calmette-Guerin (BCG) instillation for initial dose or series. BCG is initiated within 6 months of the bladder cancer staging. In the sample calculation provided at the end of the eCQM flow, the Numerator is equal to 40 patients.

Denominator Exceptions
The Denominator Exceptions criteria identify patients from the Denominator that did not meet the Numerator population criteria due to unavailability of BCG within 6 months after bladder

cancer staging. In the sample calculation provided at the end of the eCQM flow, the Denominator Exceptions are equal to 10 patients.

Sample Calculation

A sample calculation is provided to help determine how the measure performance rate is derived. The measure performance rate is calculated by dividing the Numerator (total equals 40 patients) by the difference between the Denominator (total equals 100 patients), the Denominator Exclusions (total equals 20 patients), and the Denominator Exceptions (total equals 10 patients) which is equal to a score of 57 percent.